Under construction – not a live service
Sign in
Taking people in JapanPhase 2

Tests follow-up bone drugs after denosumab in Japanese people with osteoporosis

Compares bone drug treatments in people with osteoporosis after 2 years of denosumab.

Plain-language title generated from the registry record
Registry title: Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

Key facts

Where
Matsumoto, JapanSee the site
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Japanese osteoporosis patients who have finished 2 years of denosumab treatment. It compares three follow-up drug plans.

Age
20 to 120 years
Sex
Men and women can join.
Disease stage
Osteoporosis. No stage or severity is given.
Earlier treatment
2 years of denosumab treatment before joining.

Main reasons for not taking part

  • Allergy to the study drugs
  • Refusing to take part in the research
  • Pregnancy

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 20 and 120 years old?

Source: NCT03755193, who can take part

Where in Japan

  • Yukio NakamuraMatsumoto, JapanContact: Yukio Nakamura, MD, PhDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Shinshu University
Trial code
NCT03755193
Record updated
21 September 2021
Original description
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy:Read full original descriptionShow less

Examination of Efficacy and Safety of SERM or Bisphosphonates After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy:

SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months

Inclusion: osteoporosis patients.

Exclusion: not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant.

ClinicalTrials.gov NCT03755193